VisionGate outlines plan to relocate to Phoenix; Glaxo gets Swiss OK for BHP drug; Panacea gets govt bucks for swine flu vax;

 @FierceBiotech: Roll Call's list of highest paid trade association lobbyists, with PhRMA/BIO accounting for 8 of top 20. Article | Follow @FierceBiotech

 @JohnCFierce: RT @adamfeuerstein: $CTIC Voting Question: Does this single, incomplete trial of pixantrone adequate to support approval? Yes: 0, No: 9. | Follow @JohnCFierce

> VisionGate has announced plans to move its headquarters and 21 employees from Seattle to Phoenix, and the company plans to add 25 workers in the 18 months following the relocation. The city of Phoenix is paying $1.2 million for new 3-D imaging devices that the biotech company uses to watch cells turn cancerous. As part of the deal other researchers will be allowed to use the devices. Report

> GlaxoSmithKline says it won Swiss approval of Duodart, a two-in-one therapy for benign prostatic hyperplasia. This is the first European approval for the drug. Report

> India's Panacea Biotec has gained government financing for the development of a swine flu vaccine. Story

> Martek Biosciences has acquired Amerifit Brands--a health and wellness company--for $200 million in cash. Report

> BrainStorm has gained a $2 million investment that will be used to help fund new work on amyotrophic lateral sclerosis. Report

And Finally... Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.